

# Index

Page numbers in *italics* refer to figures; those in **bold** to tables.

- ACE inhibitors, 24
- acute chest pain, 6
- acute coronary syndrome, **219–20**
- acute myocardial infarction (AMI), 153
- adults, young, 103
- age, 24, 49, 86
- ambispective data collection, **46**, 47–48
- AMI *see* acute myocardial infarction
- angiography, 3, **5**
  - classic, 8
  - coronary, 9
  - renal, 119, **121**
- Annals of Internal Medicine*, 171, 218
- anorexia nervosa, 24
- antibiotics, 222
- anticoagulation, intravenous, 66, **66**, 66–68
- anxiety, 53
- appendicitis, 34–36, **35**, **36**, 101
- architecture of diagnostic research
  - introduction to, 21–24
  - questions regarding, 20–21, 25–40, **26**, **27**, **29**, **30**, 31, **35**, **36**, **37**, **38**, 39, **40**
- area under the curve (AUC), 6, 221
- area under the ROC curve (AUROC), 6, 151, 156, 224
- artificial variation, 101
- aspiration pneumonia, 74, 74–75
- aspirin, **68**, 68–69
- AUC *see* area under the curve
- AUROC *see* area under the ROC curve
- Bayes's theorem, 36, 50, 161, 164, 237, 242, 249
  - clinical problem solving/diagnostic decision making and, 242–43, 246
  - formal application of, 238, 245
  - formulation of, 119, 131–32, 132
  - logistic regression, 134–36
  - implication of, 118–19
- benign prostatic hyperplasia, 52
- bias(es)
  - confirmation, 246
  - in diagnostic accuracy studies, 168–71
  - examples of, 222
  - incorporation, 42, 53, 222
  - observer, 1, 10
  - potential, 14
  - in processing information, 245–46
  - selection, 1, 250–51
    - evaluation of, **4**, 8–9
  - spectrum, 222
  - workup, 192
  - see also* selection; spectrum
- biomarkers, 171
- biomedical knowledge, 273
  - developments of, 277
  - progress of, 278
- bivariate model, 180, 209
- bivariate techniques, 43, **57**, 58
- blinding, 10, 51, 53, 54, 89
  - allocation, 78
  - procedures, 83
- blood
  - flow, 8
  - pressure, 23, 24
  - sugar, 24
  - tests, **5**, 6, 10
- BNP (B-type natriuretic peptide), 22
- breast(s)
  - cancer
    - detection of, 49
    - screening programs, 14
    - women with, 75
  - fibroadenomatosis of, 49
- BRHS *see* British Regional Heart Study
- British Journal of Cancer*, 176
- British Medical Journal*, 171, 218
- British Regional Heart Study (BRHS), 225
- B-type natriuretic peptide *see* BNP

286 Index

- calibration, 222, 224
  - predictive values and, 98, **100**
  - of tests, 98, **100, 106**, 106–7
  - variation in, 108–9
- cancer *see* breast cancer
- cardiovascular diseases (CVDs)
  - clinical example-validation studies of
    - primary prevention of, 224–26, 226
  - impact analysis studies of primary prevention of, 228–29, **229**
- cardiovascular risk functions, 233
- CARE (Clinical Assessment of the Reliability of the Examination), 36, 215
- carotid diseases
  - management of, 64
  - severity of, 65
- carotid stenoses, 15
- CART *see* classification and regression tree software
- case-control studies, 13
- case-referent approach, 42, **46**, 46–47
- CDSSs (computer-based clinical decision support systems)
  - implementation of, 216, 229–30
  - links to, 213, 214
- CENTRAL, 182
- “certainty effect” violations, 244
- cervical bruit
  - duplex ultrasonography and, 68, 68
  - without previous cerebrovascular disease, 64–65, **65**
- cesarean section, vaginal birth after
  - previous, **219–20**
- CHD *see* coronary heart disease
- chest pain, acute, 6
- children, 103
- cholesterol
  - levels of, 24
  - serum, 23
- CINAHL *see* Cumulative Index of Nursing and Allied Health
- CIs *see* Confidence Intervals
- classification and regression tree software (CART), **160**
  - characteristics of, 149–50
  - diagnostic outcomes and, 149
  - example of, 150
  - indicators of diagnostic accuracy
    - studies and, 149
  - interactions, 149
  - problems shared with, 155–58
  - sequence in, 149
  - use of, 149
- Clinical Assessment of the Reliability of the Examination *see* CARE
- Clinical Chemistry*, 171, 175
- clinical decision
  - analysis, 12, **12**, 275, 277
  - approach, 15
- clinical epidemiological quality, 278
- clinical practice, integration of
  - information in, 15–16
- Clinical Prediction Rules (CPRs), 15
  - application of, 213
  - clinical context of, 214–15
  - conclusions on, 222, **223, 229**, 232
  - coverage and description of, 218–21, **219–20**
  - definition of, 213
  - derivation and, 222–23, **223**
  - heuristics of decision making and, 215–16
  - impact analysis for, 226–32, 227, **229**, 231
  - implementation of, 213, 229–30
  - introduction to, 214
  - levels of evidence/methodological standards and, 221–26, 222, **223**, 226
  - methodological challenges with, 221
  - recommended key references for, 233
  - thresholds approach to diagnosis and, 216–18, 217
  - usage of, 213
- clinical problem solving, 274–76
  - diagnostic decision making and
    - Bayes theorem, 242–43, 246
  - categorization/pattern recognition and, 240–41
  - conclusions on, 249–51
  - educational implications for, 248–49
  - errors in hypothesis
    - generation/restructuring and, 241–42

- errors in probability estimation and, 243–45
- errors in probability revision and, 245–46
- as hypothesis selection, 238–39
- hypothetico-deductive method and, 239–40
- introduction to, 237–38
- methodological guidelines for, 249–51
- as opinion revision, 242–43
- two-system theories of cognition and, 247–48, 248
- clinical studies, **4**, 12–14
- clinical validity, 59, 281
- Cochrane Collaboration, 14, 171, 172, 232
- coefficient of variation (CV), 50
- cognition, two-system theories of, 247–48, 248
- cohort studies, 13
- comorbidity, 49, 86
- compression errors, 244
- computed tomography (CT), **5**, **8**, 10–11, 110
- computer-based clinical decision support systems *see* CDSSs
- concealment, 78
- Confidence Intervals (CIs), **67**, 68–69
  - data analysis of diagnostic tests’
    - accuracy, **121**, 122–23, **123**
  - tables
    - for proportions, **137–44**
    - for Renal Artery Stenosis, 137, **144**
    - for small *n*, **138–41**
- confounding
  - probability and values of outcomes, 246
  - variables
    - control of, 49–50
    - definition of, 49
    - effect of, 87
    - use of, 50
- consensus methods, **12**, 12–13
- conservatism, 245
- CONSORT, 171–72, 175
- coronary angiography, 9
- coronary artery diseases, 27, **27**
- coronary heart disease (CHD), 225
- coronary syndrome, acute, **219–20**
- cost-benefit analysis, 268
- cost-consequence analysis, 268–69
- cost-effectiveness analysis, 267
- cost-effectiveness studies, 2, 6, 11–12, **12**
- cost-minimization analysis, 266–67
- cost-utility analysis, 267–68
- CPRs *see* Clinical Prediction Rules
- CPT *see* cumulative prospect theory
- cross-sectional studies, 1
  - accuracy of diagnostic testing and, 42–44
  - adverse effects of reference standard, **56**, 57
  - adverse effects of test, **56**, 57
  - basic steps in diagnostic research and, 44
  - case-referent approach to, 42, **46**, 46–47
  - concluding remarks on, 60
  - determinants and, 48–50, **49**
  - direction of data collection, **46**, 47–48
  - evaluation of contrast and, 44–46, **45**
  - external validation of, 59
  - general approach to, **46**, 46–47
  - modifiers of, 49
  - “occurrence relation” and, 48–50, **49**
  - outline of study question and, **46**, 46–48
  - pragmatic criteria for, 52–55
  - reference standard outcome and, 42, 50–52, **51**
  - reproducibility and, 50
  - research question for, 44–46, **45**
  - specification of study population and, 55–57, **56**
  - test based enrollment and, **46**, 46–47
- delayed type, 8
- pragmatic criteria for, 52–55
  - clinical follow-up in, 53
  - independent expert panel and, 52
  - prognostic criterion for, 54–55
  - standard shift and, 55

**288** Index

- cross-sectional studies (*cont.*)
  - tailor-made reference standard protocol and, 53–54
  - survey, 12, **12**
    - see also* research designs
- CT *see* computed tomography
- Cumulative Index of Nursing and Allied Health (CINAHL), 183, 185*b*–191*b*
- cumulative prospect theory (CPT), 244
- CV *See* coefficient of variation
- CVDs *see* cardiovascular diseases
- DARE *see* Database of Abstracts of Reviews of Effects
- DAs *see* decision aids
- data
  - analysis, 118–45, **195**
    - CIs and, **121**, 122–23, **123**
    - clinical example of, 119–20, **120**
    - concepts and questions regarding, 120–21
    - concluding remarks on, 136
    - ER with, 125–26, 137, **142–44**
    - introduction to, 119
    - LR and, 126–27, 129–34, 130, 132
    - multivariable, 146–66
    - negative/positive predictive values with, 124–25, 137, **142–44**
    - optimal cutoff value and, **133**, 133–34
    - posttest probability of disease with, 124–25, 137, **142–44**
    - pretest probability of disease with, 124–25, 137, **142–44**
    - sampling variability and, **121**, 122–23, **123**
    - sensitivity of, **121**, 121–22, 132, **133**, 134
    - software for, 136–37
    - specificity for, **121**, 121–22
    - theory and guide to tables in appendix, 123–24
  - collection
    - ambispective, **46**, 47–48
    - prospective, **46**, 47–48
    - retrospective, **46**, 47–48
  - extraction, **192**, 194
  - history data, 3
  - interpretation with
    - hypothetico-deductive method, 239–40
  - laboratory data, 3
  - meta-analyses of pooled, 14, 180, 201–9
  - presentation, 185*b*–191*b*, 203–5, 204*b*
- Database of Abstracts of Reviews of Effects (DARE), 183, 185*b*–191*b*
- databases for conducting systemic reviews of diagnostic accuracy studies, 182–83, 185*b*–191*b*
  - other, 207–8
- deaths, 65
- decision aids (DAs), 214, 232
- decision making, heuristics of, 215–16
- decision tree, 15, 147–49
- delayed type cross-sectional studies, 8
- depression, 52
- derivation, 222–23, **223**
- Derivation and Validation of a Clinical Prediction Rule, **223**, 223–24
- design options, 12
- determinant(s)
  - operationalize, 44
  - of primary interest, 42, 48–50, **49**
- diagnostic accuracy studies
  - biases in, 168–71
  - conducting systemic reviews of, 180, 273
    - bivariate model for, 180, 209
    - comments on, 183–84
    - data analysis for, 195
    - data extraction for, **192**, 194
    - data presentation for, 185*b*–191*b*, 203–5, 204*b*
    - discussion on, 205–6
    - documentation of, 183
    - heterogeneity in, 196–97, 198–200, 199*b*
    - HSROC model for, 209
    - introduction to, 181
    - literature search for, 181–82
    - methodological quality of, 184–94
    - notation and, 208
    - results of individual studies and, 195

- retrieval of articles and inclusion criteria in, 183–84
- search and selection process with, 206
- search strategy for, 182
- SROC and, 180, 208–9
- statistical pooling and, 201–3
- threshold (cut-point) effect in, 197, 198*b*
- usage of statistical models and, 200
- cross-sectional study, 42–62
- data analysis of accuracy studies, 118–45
- databases for conducting systemic reviews of, 182–83, 185*b*–191*b*
  - other, 207–8
- meta-analyses in, 158
- multivariable analysis in
  - additional methods in, 154
  - CART software as, 149–50, 155–58, **160**
  - characteristics from logistic regression analysis and, 136, 158–64, 159, **160**, **162**, 163
  - introduction to, 146–47
  - latent class analysis as, 154–58
  - logistic regression analysis as, 150–52, 155–58
  - manipulated logistic regression analysis as, 152–53, 155–58, **160**
  - methods' overview of, 147–55
  - neural networks as, 153, 155–58
  - overlapping subgroups with, 156–57
  - performance of final model in, 156, 157
  - problems shared by all methods of, 155–58
  - recommendations for, 158
  - simple tree building as, 147–49, 155–58, **160**
- standards of reporting on
  - bias and variability in, 168–71
  - introduction to, 167–68
  - other initiatives in, 176
  - STARD statement and, 171–72, **173–74**, 175
  - uptake of STARD in, 172–76
- tests, 2, 42–43
  - assessment of clinical course/severity of diagnosed condition and, 43
  - bivariate techniques for, 43, **57**, 58
  - case-referent approach, 42, **46**, 46–47
  - cross-sectional studies and, 42–44
    - adverse effects of reference standard, **56**, 57
    - adverse effects of test, **56**, 57
    - basic steps in diagnostic research and, 44
    - case-referent approach to, 42, **46**, 46–47
    - concluding remarks on, 60
    - determinants and, 48–50, **49**
    - direction of data collection, **46**, 47–48
    - evaluation of contrast and, 44–46, **45**
    - external validation of, 59
    - general approach to, **46**, 46–47
    - modifiers of, 49
    - “occurrence relation” and, 48–50, **49**
    - outline of study question and, **46**, 46–48
    - pragmatic criteria for, 52–55
    - reference standard outcome and, 42, 50–52, **51**
    - reproducibility and, 50
    - research question for, 44–46, **45**
    - specification of study population and, 55–57, **56**
    - test based enrollment and, **46**, 46–47
  - data analysis of
    - clinical example of, 119–20, **120**
    - concepts and questions regarding, 120–21
    - concluding remarks on, 136
    - confidence intervals and, **121**, 122–23, **123**, **137–44**
    - error rate with, 125–26, 137, **142–44**
    - introduction to, 119
    - likelihood ratios and, 126–27, 129–34, 130, 132

290 Index

- diagnostic accuracy studies (*cont.*)
  - negative/positive predictive values with, 124–25, 137, **142–44**
  - optimal cutoff value and, **133**, 133–34
  - posttest probability of disease with, 124–25, 137, **142–44**
  - pretest probability of disease with, 124–25, 137, **142–44**
  - sampling variability and, **121**, 122–23, **123**
  - sensitivity of, **121**, 121–22, *132*, **133**, 134
  - software for, 136–37
  - specificity for, **121**, 121–22
  - theory and guide to tables in appendix, 123–24
  - external validation of, 43
  - general design types for, 42
  - inclusion criteria for, 43
  - introduction to, 43–44
  - multivariable techniques for, 43, **57**, **58**
  - recruitment procedure for, 43
  - steps for, 42
  - survey of total study population, 42, **46**, 46–47
  - test-based enrollment, 42
- Diagnostic and Screening Tests Methods Working Group (Cochrane Collaboration), 171
- Diagnostic and Statistical Manual of Mental Disorders (DSM), 149
- diagnostic before-after study, 83–95
  - for evaluation of clinical impact of single or additional testing, 83
  - introduction to, 84
  - research questions and
    - concluding remarks on, 93–94
    - diagnostic testing and, 89–90
    - example of, 84–86, **85**, **85**
    - general model of, 86, 86–88
    - limitations of, 87, 93
    - modified approaches to, 93
    - posttest outcome and, 90–91, 91
    - pretest baseline and, 88–89
    - sample analysis/size and, 92
    - selection of study subjects and, 91–92
    - time factor with, 91, *91*
    - time factor with, 91, *91*
- diagnostic decision making
  - clinical problem solving and, 274–76
    - Bayes theorem, 242–43, 246
    - categorization/pattern recognition and, 240–41
    - conclusions on, 249–51
    - educational implications for, 248–49
    - errors in hypothesis generation/restructuring and, 241–42
    - errors in probability estimation and, 243–45
    - errors in probability revision and, 245–46
    - as hypothesis selection, 238–39
    - hypothetico-deductive method and, 239–40
    - introduction to, 237–38
    - methodological guidelines for, 249–51
    - as opinion revision, 242–43
    - two-system theories of cognition and, 247–48, *248*
  - diagnostic evaluation, funding of, 2
  - diagnostic odds ratio (DOR), **121**, 127, 195, 201
  - diagnostic problems, research on, 273, 278
  - diagnostic procedures, evaluation strategy
    - challenges to, 277–80
    - efficiency and speed of, 280
    - evaluation of, 273
    - important steps towards, 274–77, 275
    - introduction to, 274
    - study designs and, 277
  - diagnostic research, 281–82
    - architecture of
      - introduction to, 21–24
      - questions regarding, 20–21, 25–40, **26**, **27**, **29**, **30**, *31*, **35**, **36**, **37**, **38**, *39*, **40**

- comprehensiveness of, 2
- designs, 11–16, **12**
- methodology of, 1, 2
- Phase I questions, 20, 25–27, **26**
- Phase II questions, 20, 25, **27**, 27–28, **29**
- Phase III questions, 21, 25, 28–31, **30**, **31**
  - applicability of, 34–36, **35**, **36**
  - limits, 34
  - validity of, 32, 32–34
- Phase IV questions, 21, 25, **37**, 37–38, **38**
- Phase V questions, 21, 25, 38–40, 39, **40**
- synthesizing, 14–15
- diagnostic systematic reviews, 1, 12, 14, **29**, **180–212**
- diagnostic technologies
  - conclusions on, 16
  - development of, 1
  - introduction to, 2–3
  - methodological challenges to, 8–11
    - complex relations within, 7
    - “gold standard” problem and, 7–8
    - “soft” measures within, 9
  - objectives of, 1, 3–7, **4**, **5**
- diagnostic test(s)
  - “abnormal,” 20
  - application of, 217–18
  - diagnostic before-after study and, 89–90
  - discrimination of, 3, **5**
  - effectiveness/validity of, 2
  - “normal,” 20, 21–24
  - “normal range,” 21–24
  - objectives of, 1, 3–7, **4**, **5**
  - pathophysiological
    - concepts/developments for, 42–43
- RCTs
  - alternative randomized designs and, 69–71, **70**
  - comparison of test strategies and, 71, 71–76, **72**, **73**, 74, 76
  - conclusions on, 80
  - design choices for, **77**, 77–78
  - measurement of, 64–69, 65, **66**, 66, **67**, 68, **69**
  - practical issues regarding, 78–80, 79
  - prognostic impact of, 63–64
  - research on, 2
  - technical developments for, 42–43
- diagnostic tests, accuracy of, 2, 42–43
  - assessment of clinical course/severity
    - of diagnosed condition and, 43
  - bivariate techniques for, 43, **57**, 58
  - case-referent approach, 42, **46**, 46–47
  - cross-sectional studies and, 42–44
    - adverse effects of reference standard, **56**, 57
    - adverse effects of test, **56**, 57
  - basic steps in diagnostic research and, 44
  - concluding remarks on, 60
  - determinants and, 48–50, **49**
  - direction of data collection, **46**, 47–48
  - evaluation of contrast and, 44–46, **45**
  - external validation of, 59
  - general approach to, **46**, 46–47
  - modifiers of, 49
  - “occurrence relation” and, 48–50, **49**
  - outline of study question and, **46**, 46–48
  - pragmatic criteria for, 52–55
  - reference standard outcome and, 42, 50–52, **51**
  - reproducibility and, 50
  - research question for, 44–46, **45**
  - specification of study population and, 55–57, **56**
  - test based enrollment and, **46**, 46–47
- data analysis of
  - clinical example of, 119–20, **120**
  - concepts and questions regarding, 120–21
  - concluding remarks on, 136
  - Confidence Intervals and, **121**, 122–23, **123**, **137–44**
  - Error rate and, 125–26, 137, **142–44**
  - introduction to, 119

**292** Index

- diagnostic tests, accuracy of (*cont.*)
  - Likelihood Ratios and, 126–27, 129–34, 130, 132
  - negative/positive predictive values with, 124–25, 137, **142–44**
  - optimal cutoff value and, **133**, 133–34
  - posttest probability of disease with, 124–25, 137, **142–44**
  - pretest probability of disease with, 124–25, 137, **142–44**
  - sampling variability and, **121**, 122–23, **123**
  - sensitivity, **121**, 121–22, 132, **133**, 134
  - software, 136–37
  - specificity, **121**, 121–22
  - theory and guide to tables in appendix, 123–24
- external validation of, 43, 59, 96–117, 223–24
- general design types for, 42
- inclusion criteria for, 43
- introduction to, 43–44
- multivariable techniques for, 43, **57**, 58
- recruitment procedure for, 43
- steps for, 42
- survey of total study population, 42, **46**, 46–47
- test-based enrollment, 42
- dichotomization
  - of continuous tests, 127–31, **128**, 129, **129**, 130, **131**
  - occurrence of, 128, **129**
- discrimination
  - assessment of, 11
  - of diagnostic tests, 3, **5**
  - measures of, 3, **4**, 13
  - predictive values and, 98, **100**
  - test accuracy and, 98, **100**, 106, **106**, 110
  - usefulness of, 10
  - variation in, 108–9
- discriminatory power, 107–8
- disease(s)
  - absence/presence of, **162**
  - carotid
    - management of, 64
    - severity of, 65
  - cervical bruit without previous cerebrovascular, 64–65, **65**
- CVDs
  - clinical example-validation studies of primary prevention of, 224–26, 226
  - impact analysis studies of primary prevention of, 228–29, **229**
  - definition of, 99
  - estimation of probability of, 98
  - groups across settings, 99–100, **100**
  - spectrum of, 103–4
  - posttest probability of, 124–25, 137, **142–44**
  - pretest probability of, 124–25, 137, **142–44**
  - prognosis of, 2
- disorder(s)
  - clinical course of, 6
  - detection/exclusion of, 3, **4**
  - indication area of, 10–11
  - target
    - “gold standard” of, 50
    - Phase I questions and, 20, 25–27, **26**
    - Phase II questions and, 20, 25, **27**, 27–28, **29**
    - Phase III questions and, 21, 25, 28–31, **30**, 31
    - as primary dependent or outcome variable, 42, 48–50, **49**
    - reference standard outcome of, 42, 50–52, **51**
- DNA, 55, 278
- doctors *see* physician(s)
- DOR *see* diagnostic odds ratio
- drug(s)
  - antihypertensive, 24
  - control of, 16
  - quality of, 16
  - safety of, 2
- DSM *see* Diagnostic and Statistical Manual of Mental Disorders
- duplex ultrasonography
  - accuracy of, **68**, 69
  - acute strokes and, 66, **66**, 66–68
  - cervical bruit and, 68, 68
  - performance of, 65–66
  - prognostic value of, **66**

- dyspepsia, 76  
dysphagia, 74, 74–75
- EBM *see* evidence-based medicine  
ECG *see* electrocardiogram  
echocardiography, 30  
elderly, 103  
electrocardiogram (ECG)  
  exercise, 5  
    abnormal, 9  
    accuracy of, 54  
    routine, 6  
Electronic Patient Record (EPR), 214, 228, 232  
EMBASE (Excerpta Medica Database), 182–83, 185*b*–191*b*  
EMBASE ALERT, 185*b*–191*b*  
endoscopy, 76  
EPR *see* Electronic Patient Record  
ER *see* error rate  
error(s)  
  compression, 244  
  in hypothesis  
    generation/restructuring, 241–42  
  in probability estimation, 243–45  
  in probability revision, 245–46  
  in reference standard, 109  
error rate (ER)  
  concept, 125–26, 137, **142–44**  
  as measure, 133  
erythrocyte sedimentation rate (ESR), 50  
  diagnostic impact of, 84–86, **85**, 85  
  GPs and impact of, 84–86, **85**, 85  
  test characteristics of, 85–86  
ESR *see* erythrocyte sedimentation rate  
*European Journal of Cancer*, 176  
evaluation strategy, overview, 273–77  
evidence-based medicine (EBM), 243, 249, 256  
Excerpta Medica Database *see* EMBASE  
exercise  
  ECG, 5  
  fitness and, 24  
“eyeball test,” 196
- false negatives (FN), 133–34  
false positives (FP), 133–34
- FESST *see* flexible endoscopic valuation  
  of swallowing with sensory testing
- fibroadenomatosis, of breasts, 49  
fitness, exercise and, 24  
  *see also* physical fitness  
fixed effect  
  model, 200  
  pooling, 201  
flexible endoscopic valuation of  
  swallowing with sensory testing (FESST), 74, 74–75  
FN *see* false negatives  
forward tracking, 182  
FP *see* false positives  
fracture rates, 98  
Framingham risk functions, 225–26, 226, 228  
From Discovery to Clinical Practice:  
  Diagnostic Innovation,  
  Implementation, and  
  Evaluation *see* NCI-EORTC First  
  International Meeting on  
  Cancer Diagnostics  
funding, 2  
fuzzy-trace theory, 241, 247
- Galbraith plot, 196  
*Gale Directory of Online Portable and Internet  
  Databases*, 183  
Gaussian distribution, 20  
  definitions of, 22–23  
gender, 49, 86  
gene(s)  
  characteristics of, 278  
  expressions, 171  
general practitioners (GPs), 3, 37  
  on diagnosis of patients, 84–85, 85  
  impact of ESR and, 84–85, **85**, 85  
“gold standard,” 1  
  establishment of, 50  
  problem and methodological  
    challenges to diagnostic  
    technologies, 7–8  
  of target disorders, 50  
  tests, 21–22  
  *see also* reference standard  
GPs *see* general practitioners

294 Index

- HDL cholesterol, 225
- health
  - outcomes, 37–38
  - perspectives, 6
  - problems, 2
- health care
  - costs, 7
    - Phase V questions and, 21, 25, 38–40, 39, **40**
  - delivery, 269
  - quality of, 2
  - systems, 24
    - see also* primary care; tertiary care
- heparin, unfractionated, 66, **66**, 66–68
- heterogeneity
  - dealing with, 198–200, 199*b*
  - search for, 196–97
  - sources of, 180
  - studies, 200
  - when conducting systemic reviews of diagnostic accuracy studies, 196–97, 198–200, 199*b*
- hierarchical SROC *see* HSROC
- Hosmer-Lemeshow goodness-of-fit test, 224
- hospitals, emergency departments of, 3
- H Pylori*, 76
- HSROC (hierarchical SROC), 201–2, 209
- human chorionic gonadotrophin *see* serum hCG
- hyperplasia, benign prostatic, 52
- hypertension, 23, 119–20, **120**
- hypothesis
  - generation/restructuring, errors in, 241–42
  - selection, 238–39
- hypothetico-deductive method
  - clinical problem solving/diagnostic decision making and, 239–40
  - data interpretation with, 239–40
  - early, 239
- ICT *see* Information and Communication Technology
- IFCC *see* International Federation of Clinical Chemistry
- illness(s)
  - clinical course of, 6
  - symptoms of, 2
- imaging techniques, 8
- impact analysis, 226–32, 227, **229**, 231
- inclusion criteria
  - accuracy of diagnostic tests, 43
  - conducting systemic reviews of diagnostic accuracy studies, retrieval of articles and, 183–84
  - incremental value, 105–8
- independence, 32
- index test *see* duplex ultrasonography
- indication area, 10–11
- Information and Communication Technology (ICT), 15–16, 213, 230–31, 232
  - development of, 273, 277–78
  - methodological agenda and, 278–79
- International Federation of Clinical Chemistry (IFCC), 183
- intravenous anticoagulation, 66, **66**, 66–68
- irritable bowel syndrome, 52
- Japan Information Centre of Science and Technology File on Science, Technology and Medicine (JICST-E), 183, 185*b*–191*b*
- JICST-E *see* Japan Information Centre of Science and Technology File on Science, Technology and Medicine
  - Journal of Clinical Oncology*, 176
  - Journal of National Cancer Institute*, 176
  - Journal of the American Medical Association*, 218
- knowledge
  - biomedical, 273
  - developments of, 277
  - progress of, 278
- language, 184
- latent class analysis, 154–58
  - characteristics of, 154–55
  - example of, 155
  - problems shared with, 155–58

- Latin American Caribbean Health Sciences Literature (LILACS), 183
- LBBB *see* left bundle branch block
- left bundle branch block (LBBB), 153
- left ventricular dysfunction (LVD), 22
  - Phase I questions and, 20, 25–27, **26**
  - Phase II questions and, 20, 25, **27**, 27–28, **29**
  - Phase III questions and, 21, 25, 28–31, **30**, **31**
    - applicability of, 34–36, **35**, **36**
    - limits, 34
    - validity of, 32, 32–34
  - Phase IV questions and, 21, 25, **37**, 37–38, **38**
  - Phase V questions and, 21, 25, 38–40, **39**, **40**
  - treatments for, 24
- life, quality of, 6
- Likelihood Ratio (LR), 3, **4**, 21
  - calculation of, 72
  - data analysis of accuracy of diagnostic tests, 126–27, 129–34, 130, 132
  - informative value of test results and, 118
  - of a negative result, **5**
  - of a positive result, **5**
- LILACS *see* Latin American Caribbean Health Sciences Literature
- liver
  - biopsy, 8
  - function tests, 3
  - pathology, 8
- logistic regression, 134–36, 221
  - analysis, 158–64, 159, **160**, **162**, 163
    - characteristics of, 134, 150–52
    - example of, 135, 152
    - interactions in, 151
    - problems shared with, 155–58
  - formulation of Bayes theorem, 134–36
  - function, 159
- LR *see* Likelihood Ratio
- LVD *see* left ventricular dysfunction
- magnetic resonance imaging (MRI), 10, 50
- mammography, 49
- maneuvers, **29**
- manipulated logistic regression analysis, **160**
  - characteristics of, 152
  - example of, 152–53
  - problems shared with, 155–58
- MBS *see* modified barium swallowing
  - swallow test
- Medion, 183, 188
- MEDLINE, 182–83, 185*b*–191*b*
- Mencken, H.L., 23
- MeSH, 182, 185*b*–191*b*
- meta-analyses, 1, 12, **12**, 59, 180, 275, 276
  - in diagnostic accuracy studies, 158
  - monitoring, 6
  - of pooled data, 14
- migraines, 52
- modified barium swallow test (MBS), 74, 74–75
- modifiers of diagnostic test accuracy, 49
- monitoring, 6
- morality, 23
- mortality, 14, **219–20**
- MRI *see* magnetic resonance imaging
- multivariable analysis
  - in diagnostic accuracy studies
    - additional methods in, 154
    - CART software as, 149–50, 155–58, **160**
    - characteristics from logistic regression analysis and, 158–64, 159, **160**, **162**, 163
    - introduction to, 146–47
    - latent class analysis as, 154–58
    - logistic regression analysis as, 136, 150–52, 155–58
    - manipulated logistic regression analysis as, 152–53, 155–58, **160**
    - methods' overview of, 147–55
    - neural networks as, 153, 155–58
    - overlapping subgroups, 156–57
    - performance of final model in, 156, 157
    - problems shared by all methods of, 155–58
    - recommendations for, 158
    - simple tree building as, 147–49, 155–58, **160**

296 Index

- Murphy, Tony, 22  
myocardial infarction, **5**, 6, 65, 153, 156  
myocardial infarction, acute, 153
- natural prognostic value, 67, **67**  
*Nature Clinical Practice Oncology*, 176  
NCI-EORTC First International Meeting  
on Cancer Diagnostics (From  
Discovery to Clinical Practice:  
Diagnostic Innovation,  
Implementation, and  
Evaluation), 176  
negative predictive values (NPVs),  
124–25, 137, **142–44**
- neural networks  
advantages of, 153  
example of, 153  
as multivariable analysis, 153, 155–58  
problems shared with, 155–58  
*New England Journal of Medicine*, 218  
New Zealand, 37  
NHS Centre for Reviews and  
Dissemination, 183  
nomograms, 31, 31  
normal, 22  
cultural desirability, 23  
diagnostic definition of, 24  
Gaussian definition of, 22  
percentile, 22  
risk factor definition, 23  
therapeutic definition of, 24  
notation, 208  
NPVs *see* negative predictive values
- obesity, 23  
objectives  
of diagnostic testing, 1, 3–7, **4**, **5**  
of STARD, 171–72  
observer(s)  
biases, 1, 10  
variability, 1, 10  
“occurrence relation,” 48–50, **49**  
odds ratio (OR), **4**, **5**, 98, **121**, 127  
OLDMEDLINE, 185*b*–191*b*  
OR *See* odds ratio  
osteoporosis, 98  
outcome(s), **29**  
diagnostic and CART, 149  
health, 37–38  
posttest, 90–91, 91  
of target disorders, reference standard,  
42, 50–52, **51**  
in ultrasonography  
abnormal, 78–79, 79  
normal, 78–79, 79  
variable, target disorders as primary  
dependent or, 42, 48–50, **49**  
overemphasizing rare conditions, 243
- pain, 9  
PASCAL, 185*b*–191*b*  
pathophysiological concepts, 42  
patient(s), 6  
changing roles of, 273, 279–80  
characteristics of, 3, 49, 86  
condition of, 3  
diagnosis of, 85  
health of, 54, 88  
history of, 3, 21  
population, 91–92  
referral, selective of, **105**  
selection of, **29**  
status of, 90  
patient, intervention, comparator, and  
outcome (PICO), 101  
pattern recognition, 240–41  
PEG *see* percutaneous endoscopic  
gastrostomy  
percentiles, 22–23  
percutaneous endoscopic gastrostomy  
(PEG), 75  
personal digital assistants (PDAs), 230–31  
Phase I questions, 20, 25–27, **26**  
prospective identification of subjects  
and, **46**, 47–48  
retrospective identification of subjects  
and, **46**, 47–48  
Phase II questions, 20, 25, **27**, 27–28, **29**  
prospective identification of subjects  
and, **46**, 47–48  
retrospective identification of subjects  
and, **46**, 47–48  
Phase III questions, 21, 25, 28–31, **30**, 31  
applicability of, 34–36, **35**, **36**  
limits, 34  
prospective identification of subjects  
and, **46**, 47–48  
validity of, 32, 32–34

- Phase IV questions, 21, 25, **37**, 37–38, **38**
- Phase V questions, 21, 25, 38–40, 39, **40**
- physical examination, 3, 21
- physical fitness, 6
- physician(s)
  - assessment of, 83, 86
  - experience and skills, 86
  - management by, 14
- PICO *see* patient, intervention, comparator, and outcome
- placebo, 66, **66**, 66–68
- pneumonia, aspiration, 74, 74–75
- population, 184
  - clinical question and, 102–7, **103**, **104**, **105**, **106**, 106, **107**, 110, 111
  - indicated, 13
  - study
    - candidate, 55
    - indicated, 55, **56**
    - intended, 55
    - “intention to diagnose,” 43, 55–56, **56**
    - “intention to screen,” 43, 56, **56**
    - intention to test, 43, **56**
    - “reference,” 22
    - subgroups within, 112
    - survey of total, 42, **46**, 46–48
    - variability of results within, 111
- positive predictive values (PPVs), 124–25, 137, **142–44**
- posterior probability, 4
  - see also* posttest probability
- posttest outcomes, 90–91, 91
- posttest probability, 4, 216
  - basic determinant of, 50
  - of disease, 124–25, 137, **142–44**
  - ESR and, **85**, 85, 85–86
  - see also* Bayes’s theorem; negative predictive values; positive predictive values; posterior probability; predictive values
- PPVs *see* positive predictive values
- pragmatic criteria
  - for cross-sectional studies, 52–55
  - clinical follow-up in, 53
  - independent expert panel and, 52
  - prognostic criterion for, 54–55
  - standard shift and, 55
  - tailor-made reference standard protocol and, 53–54
- predictive values, **4**, 34
  - calculation of, **72**
  - calibration, discrimination and, 98, **100**
  - see also* Bayes theorem; negative predictive values; positive predictive values; posterior probability; posttest probability
- pregnancy, 6
- pretest baseline, diagnostic before–after study and, 88–89
- pretest probability, **30**, 30–31
  - assessments and ESR, 85, **85**, 85–86
  - of disease, 124–25, 137, **142–44**
  - estimates of, 215–16
  - probability of target disorders and, 50
  - see also* Bayes Theorem
- prevalence, 113, **114**
- primary care, 35, **35**, **36**
- probability, 15
  - distortions, 244–45
  - estimation of
    - of disease, 98
    - errors in, 243–45
  - “known,” 24
  - prior, 10–11
  - revision
    - errors, 245–46
    - fixedness in, 245–46
  - values of outcomes and confounding, 246
  - see also* posttest probability; pretest probability
- problem solving, 238–39
  - diagnostic decision making and clinical, 274–76
  - categorization/pattern recognition and, 240–41
  - conclusions on, 249–51
  - educational implications for, 248–49
  - errors in hypothesis generation/restructuring and, 241–42
  - errors in probability estimation and, 243–45

**298** Index

- problem solving (*cont.*)
  - errors in probability revision and, 245–46
  - as hypothesis selection, 238–39
  - hypothetico-deductive method and, 239–40
  - introduction to, 237–38
  - methodological guidelines for, 249–51
  - as opinion revision, 242–43
  - two-system theories of cognition and, 247–48, 248
- prognosis
  - assessment of, 3
  - of diseases, 2
- prognostic value with intervention, 67, **67**
- prospective data collection, **46**, 47–48
- prospect theory (PT), 244
- prostatic hyperplasia, benign, 52
- proteomics, 171
- pseudodiagnosticity, 246
- psychiatric illnesses, 53
- PsycINFO, 185*b*–191*b*
- PT *see* prospect theory
- PubMed, 182
  
- QALY (quality adjusted life year), 276
- QUADAS (Quality Assessment of Diagnostic Accuracy Studies), 3, 192, 193*b*, 282
- quality adjusted life year *see* QALY
- Quality Assessment of Diagnostic Accuracy Studies *see* QUADAS
- quality-of-care research, 2
  
- Radiology*, 171
- random disclosure principle, 71, 73–74, 74
- random effects model, 200
- randomized controlled trials (RCTs), 1, 12, 13, 21
  - achievement of, 84
  - diagnostic testing and, 94
    - alternative randomized designs and, 69–71, **70**
    - comparison of test strategies and, 71, 71–76, **72**, **73**, 74, 76
    - conclusions on, 80
    - design choices for, **77**, 77–78
    - measurement of, 64–69, 65, **66**, 66, **67**, 68, **69**
    - practical issues regarding, 78–80, 79
    - prognostic impact of, 63–64
    - research on, 2
    - technical developments for, 42–43
  - principles of, 2
  - review of, 230
  - in test evaluation research, 63
- RAS *see* Renal Artery Stenosis
- Rational Clinical Examination, 215
- RCTs *see* randomized controlled trials
- receiver operating characteristic curve (ROC), 6, 98, 119
  - pooling of, 202–3
  - serum creatinine concentration, 128–30, 129, 130, **131**
  - for tests, 106, **106**
- red eye, **219–20**
- reference standard, 21–22
  - accuracy of, 32–34
  - adverse effects of, **56**, 57
  - errors in, 109
  - independent, 32, **32**
  - invasiveness and risks of, 57
  - misclassification of, 102
  - outcome of target disorders, 42, 50–52, **51**
  - possible problems, **51**, 52
  - possible solutions for, **51**, 52
  - principles of, 50–52, **51**
  - procedures, application of, 42–43
  - prognostic, 280–81
  - protocol, tailor-made, 53–54
  - target conditions and, 101–2, 102, 109–10
  - timing of, 170
  - see also* “gold standard”
- referral filter, **104**, 104–5, **105**
- reformulation, 241–42
- regression line, 196–97
- REMARK, 176
- renal angiography, 119, **121**
- Renal Artery Stenosis (RAS)
  - Confidence Intervals tables for, 137, **138–40**
  - detection of, 120, 203–5, 204*b*
  - diagnosis of, 123, **123**

- in hypertension, 119–20, **120**
- renography, **121**, 123
- representativeness, 244
- reproducibility, 50
- research designs, 11–16, **12**
- research questions
  - diagnostic before-after study and concluding remarks on, 93–94
  - diagnostic testing and, 89–90
  - example of, 84–86, **85**, 85
  - general model of, 86, 86–88
  - limitations of, 87, 93
  - modified approaches to, 93
  - posttest outcome and, 90–91, 91
  - pretest baseline and, 88–89
  - sample analysis/size and, 92
  - selection of study subjects and, 91–92
  - time factor with, 91, 91
- restructuring, 241–42
- retrospective data collection, **46**, 47–48
- ROC *see* receiver operating characteristic curve
- sample(s)
  - analysis, 92
  - size, 1, **57**, 57–58, **151**
    - estimation of, 43
    - requirements, 92
- sampling
  - direction of, 48
  - groups, 13
  - variability, **121**, 122–23, **123**
- SCI *see* Science Citation Index
- Science Citation Index (SCI), 185*b*–191*b*
- search
  - selection process with, 206
  - strategy for conducting systemic reviews of diagnostic accuracy studies, 182
  - terms, 182
- selection
  - biases, 1, 250–51
    - evaluation of, **4**, 8–9
  - effects, 280
- sensitivity, 9, 21, 118, 132
  - calculation of, 147, 161
  - combinations of, 195
- data analysis of accuracy of diagnostic tests, **121**, 121–22, 132, **133**, 134
  - determination of, 9
  - homogenous, 201
  - overestimation of, 222
  - tests, 3, **4**, **5**, 6
- serum cholesterol, 23
- serum creatinine concentration
  - RAS and, 127–31, **128**, 129, **129**, 130, **131**
  - ROC and, 128–30, 129, 130, **131**
  - values, **133**, 133–34
- serum hCG (human chorionic gonadotrophin), 106, **106**
- sex, 24
- simple tree building, **160**
  - calculations with, 148
  - characteristics of, 148
  - cut-points, indicators and, 148
  - example of, 149
  - imprecision and, 148
  - interactions and, 148
  - overview of, 147
  - problems shared with, 155–58
- sinusitis, 52
- small steps, 11
- smoking, 24
- Social Sciences Citation Index (SSCI), 185*b*–191*b*
- “soft” outcome measures, 1, 9
- software, 136–37
- specificity, 3, **4**, **5**, 6, 21, 118, 132, 161
  - calculation of, 147
  - combinations of, 195
  - in data analysis of accuracy of diagnostic tests, **121**, 121–22
  - homogenous, 201
  - overestimation of, 222
  - study population and accuracy of diagnostic tests/
    - cross-sectional studies, 55–57, **56**
- spectrum, 280
  - bias, 1, 222
    - evaluation of, **4**, 8–9
  - characteristics, 50
  - of disease groups, 103–4
  - of nondisease groups, 103–4

**300** Index

- SROC (Summary ROC), 180, 208–9  
  curve, 201  
  estimated, 204*b*
- SSCI *see* Social Sciences Citation Index
- Standards for the Reporting of Diagnostic  
  accuracy studies *see* STARD
- STARD (Standards for the Reporting of  
  Diagnostic accuracy studies),  
  2–3, 282  
  development of, 168, 171–72, **173–74**,  
  175  
  objective of, 171–72  
  steering committee, 172, **173–74**, 175  
  uptake of, 172–76
- statistical models, 200
- statistical pooling, 201–3
- stenosis, 65–66, **66**, 127, **128**
- strategy of evaluation, overview, 273–77
- stroke, 65, **219–20**, 224  
  duplex ultrasonography and, 66, **66**,  
  66–68  
  intravenous anticoagulation and, 66,  
  **66**, 66–68
- studies  
  case-control, 13  
  clinical, **4**, 13–14  
  cohort, 13  
  cost-effectiveness, 2, 6, 11–12, **12**  
  *see also* cross-sectional studies
- Summary ROC *see* SROC
- support theory, 244
- systemic reviews, 273, 276–77  
  diagnostic, 1, 12, 14, **29**  
  of diagnostic accuracy studies  
    databases for conducting, 182–83,  
    185*b*–191*b*  
    other, 207–8  
  of diagnostic accuracy studies,  
    conducting, 180, 273  
    bivariate model for, 180, 209  
    comments on, 183–84  
    data analysis for, 195  
    data extraction for, **192**, 194  
    data presentation for, 185*b*–191*b*,  
    203–5, 204*b*  
    discussion of, 205–6  
    documentation of, 183  
    heterogeneity for, 196–97,  
    198–200, 199*b*
- HSROC model for, 209  
  introduction to, 181  
  literature search for, 181–82  
  methodological quality of, 184–94  
  notation and, 208  
  results of individual studies and,  
  195  
  retrieval of articles and inclusion  
  criteria in, 183–84  
  search and selection process with,  
  206  
  search strategy for, 182  
  SROC and, 180, 208–9  
  statistical pooling and, 201–3  
  threshold (cut-point) effect in, 197,  
  198*b*  
  usage of statistical models and, 200
- target conditions, 101–2, 102, 109–10
- target disorder(s)  
  “gold standard” of, 50  
  Phase I questions and, 20, 25–27,  
  **26**  
  Phase II questions and, 20, 25, **27**,  
  27–28, **29**  
  Phase III questions and, 21, 25, 28–31,  
  **30**, 31  
  pretest probability of, 50  
  as primary dependent or outcome  
  variable, 42, 48–50, **49**  
  reference standard outcome of, 42,  
  50–52, **51**
- technologies *see* diagnostic technologies
- tertiary care, 35, **35**, **36**
- test(s), 1  
  application of, 89–90  
  based enrollment/cross-sectional  
  studies, **46**, 46–47  
  blood, **5**, 6, 10  
  calibration of, 98, **100**, **106**, 106–7  
  clinical impact of, 90–91, 93, 280  
  clinicochemical, 7  
  continuous  
    dichotomization of, 127–31, **128**,  
    129, **129**, 130, **131**  
    trichotomization of, 127–31, **128**,  
    129, **129**, 130, **131**  
  cutoff points, 5

- d-dimer, 104
- development, 274, 275
- dichotomous, 72, **72**, **121**, 127
- evaluation of, 43, 168
  - research, 63
- hazardous/invasive, 3
- hematological, 7
- Hosmer-Lemeshow goodness-of-fit, 224
- incremental, 107–8, 110–11
- less invasive, 3
- liver function, 3
- management and, 10
- medical
  - main effects of, 64
  - prognostic impact of, 63–64
- negatives, 105–6, **106**
- new
  - less expensive/invasive with fewer adverse side effects, **45**, 45–46
  - more expensive/invasive, **45**, 45–46
- number of, 157, 167
- ordering
  - changes in, 257–58, 259–60, 260, 262–70, 266
  - continuation and perpetuation of, 264
  - factors influencing, 258–59
  - guideline
    - development/implementation and, 259–62
  - implementation of, 262–64, 265–70, 266
  - improving, 256–57
  - introduction to, 257
- performance of, 83
  - applicability and transferability of, 101–7, 102, **103**, **104**, **105**, 106, **106**, **107**, 112–13
  - measures of, 98
- reference, 184
- replacement, 107–8, 110–11
- reproducibility, 50
- results
  - concordant, 72–73, 79
  - disclosure of, 89
  - discordant, 72–73, **73**, 79
  - distribution of, 99
  - interpretation of, 89
  - multiple categories of, 107–8
  - thresholds between categories, 99
- results and informative value of LR, 118
- ROC for, 106, **106**
- selection of, 157–58
- self-testing, 279–80
- single, 45, **45**, 57
  - diagnostic before-after study and, 83
  - evaluation of, 48–49
  - randomized designs for, 66, **66**, 66–69, **67**, 68, **69**
- triage, 45
  - as triage instrument, 75–76, 76
  - two or more, 49
- types of, 11
- urine, 7
- value of, 3, **4**
  - see also* diagnostic tests
- test accuracy, 32–33, 42, 50, 118
  - evaluation of, 273
  - transferability of, 96–97, 112–13
    - concluding remarks on, 114
    - discrimination and, 98, **100**, 106, **106**, 110
    - features that facilitate, 98–100, 99, **100**
    - introduction to, 97–98
    - main assumptions in, 99, 99–100, **100**
    - referral filter and, **104**, 104–5, **105**
    - true variability in, 98–108, 99, **100**, 102, **103**, **104**, **105**, 106, **106**, **107**
- therapeutics, 3, 24
- therapies, eradication, 76
- threshold(s)
  - approach to diagnosis and Clinical Prediction Rules, 216–18, 217
  - between categories, 99
  - (cut-point) effect, 197, 198*b*
- TIA *see* transient ischemic attack
- transient ischemic attack (TIA), 65, **219–20**
- treatment(s)
  - effect
    - in all test categories, 66, 68

**302** Index

- treatment(s) (*cont.*)
  - in test abnormal, **67**, **68**
  - in test normals, **67**, **68**
  - evaluation of, **1**
  - for LVD, **24**
  - research, **1**
- Treeage-DATA, **137**
- Triage, **75**
- trichotomization, **127–31**, **128**, **129**, **129**,  
**130**, **131**
- tuberculosis, **154–55**
- ultrasonography, **3**, **5**
  - duplex
    - accuracy of, **68**, **69**
    - acute strokes and, **66**, **66**, **66–68**
    - cervical bruit and, **68**, **68**
    - performance of, **65–66**
    - prognostic value of, **66**
  - outcomes in
    - abnormal, **78–79**, **79**
    - normal, **78–79**, **79**
  - unpublished or ongoing studies,  
**182**
  - unstable angina, **65**
  - urinary tract infection, **231**
  - vaginal birth, after previous cesarean  
section, **219–20**
  - validation
    - Clinical Prediction Rules, **223**, **223–24**
    - external, **43**, **59**, **96–117**
  - variability
    - in diagnostic accuracy studies, **50**,  
**96–117**, **168–71**
    - observer, **1**, **10**, **50**
    - of results within population, **111**
    - sampling, **121**, **122–23**, **123**
    - true, **98–108**, **99**, **100**, **102**, **103**, **104**,  
**105**, **106**, **106**, **107**
  - venous thromboembolism, **104**
  - virtual learning environment (VLEs), **231**
  - Visual Bayes, **137**
  - VLEs *see* virtual learning environment
  - weight loss/reduction, **5**, **23**
  - Wells, Philip, **34**
  - women, **23**
    - with breast cancer, **75**
    - diagnosis of, **106**
  - workup biases, **192**
  - x-rays, **7–8**, **10**, **120**